Autoimmune Hemolytic Anemia
(See also Overview of Hemolytic Anemia.)
Autoimmune hemolytic anemia is caused by autoantibodies that react with RBCs at temperatures ≥ 37° C (warm antibody hemolytic anemia) or < 37° C (cold agglutinin disease). Hemolysis is usually extravascular. The direct antiglobulin (direct Coombs) test establishes the diagnosis and may suggest the cause. Treatment depends on the cause and may include corticosteroids, splenectomy, IV immune globulin, immunosuppressants, avoidance of blood transfusions, and withdrawal of drugs.
Autoimmune hemolytic anemia is caused by abnormalities extrinsic to the RBC.
Warm antibody hemolytic anemia is the most common form of autoimmune hemolytic anemia (AIHA); it is more common among women. Autoantibodies in warm antibody hemolytic anemia generally react at temperatures ≥ 37° C. AIHA may be classified as
Some drugs (eg, alpha-methyldopa, levodopa—see Table: Drugs That Can Cause Warm Antibody Hemolytic Anemia) stimulate production of autoantibodies against Rh antigens (alpha-methyldopa-type of AIHA). Other drugs stimulate production of autoantibodies against the antibiotic–RBC-membrane complex as part of a transient hapten mechanism; the hapten may be stable (eg, high-dose penicillin, cephalosporins) or unstable (eg, quinidine, sulfonamides).
In warm antibody hemolytic anemia, hemolysis occurs primarily in the spleen and is not due to direct lysis of RBCs. It is often severe and can be fatal. Most of the autoantibodies in warm antibody hemolytic anemia are IgG. Most are panagglutinins and have limited specificity.
Cold agglutinin disease (cold antibody disease) is caused by autoantibodies that react at temperatures <37° C. Causes include
Infections tend to cause acute disease, whereas idiopathic disease (the common form in older adults) tends to be chronic. The hemolysis occurs largely in the extravascular mononuclear phagocyte system of the liver and spleen. The anemia is usually mild (Hb > 7.5 g/dL). Autoantibodies in cold agglutinin disease are usually IgM. The higher the temperature (ie, the closer to normal body temperature) at which these antibodies react with the RBC, the greater the hemolysis.
Paroxysmal cold hemoglobinuria (PCH; Donath-Landsteiner syndrome) is a rare type of cold agglutinin disease. PCH is more common in children. Hemolysis results from exposure to cold, which may even be localized (eg, from drinking cold water, from washing hands in cold water). An IgG antibody binds to the P antigen on RBCs at low temperatures and causes intravascular hemolysis after warming. It occurs most often after a nonspecific viral illness or in otherwise healthy patients, although it occurs in some patients with congenital or acquired syphilis. The severity and rapidity of development of the anemia varies and may be fulminant. In children, this disease is often self-resolving.
Drugs That Can Cause Warm Antibody Hemolytic Anemia
Symptoms of warm antibody hemolytic anemia tend to be due to the anemia. If the disorder is severe, fever, chest pain, syncope, or heart failure may occur. Mild splenomegaly is typical.
Cold agglutinin disease manifests as an acute or chronic hemolytic anemia. Other cryopathic symptoms or signs may be present (eg, acrocyanoses, Raynaud syndrome, cold-associated occlusive changes).
Symptoms of PCH may include severe pain in the back and legs, headache, vomiting, diarrhea, and passage of dark brown urine; hepatosplenomegaly may be present.
AIHA should be suspected in any patient with a hemolytic anemia (as suggested by the presence of anemia and reticulocytosis). The peripheral smear usually shows microspherocytes (and the reticulocyte count will be high. Laboratory tests typically suggest extravascular hemolysis (eg, hemosiderinuria is absent; haptoglobin levels are near normal, schistocytes are absent on smear) unless anemia is sudden and severe or PCH is the cause. Spherocytosis and a high mean corpuscular hemoglobin concentration (MCHC) are typical.
AIHA is diagnosed by detection of autoantibodies with the direct antiglobulin (direct Coombs) test. Antiglobulin serum is added to washed RBCs from the patient; agglutination indicates the presence of immunoglobulin or complement (C) bound to the RBCs. Generally IgG is present in warm antibody hemolytic anemia, and C3 (C3b and C3d) in cold antibody disease. The test is ≤ 98% sensitive for AIHA; false-negative results can occur if antibody density is very low or if the autoantibodies are IgA or IgM. In most cases of warm AIHA, the antibody is an IgG identified only as a panagglutinin, meaning the antigen specificity of the antibody can not be determined. In cold AIHA, the antibody is usually an IgM directed against the I/i carbohydrate on the RBC surface. Antibody titers can usually be determined but do not always correlate with disease activity.
The indirect antiglobulin (indirect Coombs) test is a complementary test that consists of mixing the patient’s plasma with normal RBCs to determine whether such antibodies are free in the plasma. A positive indirect antiglobulin test and a negative direct test generally indicate an alloantibody caused by pregnancy, prior transfusions, or lectin cross-reactivity rather than immune hemolysis. Even identification of a warm antibody does not define hemolysis, because 1/10,000 healthy blood donors has a positive test result.
Direct Antiglobulin (Direct Coombs) Test.
Indirect Antiglobulin (Indirect Coombs) Test.
Once AIHA has been identified by the antiglobulin test, testing should differentiate between warm antibody hemolytic anemia and cold agglutinin disease as well as the mechanism responsible for warm antibody hemolytic anemia. This determination can often be made by observing the pattern of the direct antiglobulin reaction. Three patterns are possible:
The reaction is positive with anti-IgG and negative with anti-C3. This pattern is common in idiopathic AIHA and in the drug-associated or alpha-methyldopa-type of AIHA, usually warm antibody hemolytic anemia.
The reaction is positive with anti-IgG and anti-C3. This pattern is common in patients with SLE and idiopathic AIHA, usually warm antibody hemolytic anemia, and is rare in drug-associated cases.
The reaction is positive with anti-C3 but negative with anti-IgG. This pattern occurs in cold agglutinin disease(where the antibody is most commonly an IgM). It can also occur in warm antibody hemolytic anemia when the IgG antibody is of low affinity, in some drug-associated cases, and in PCH.
Other studies can suggest the cause of AIHA but are not definitive. In cold agglutinin disease, RBCs clump on the peripheral smear, and automated cell counts often reveal an increased MCV and spuriously low Hb due to such clumping; hand warming of the tube and recounting result in values significantly closer to normal. Warm antibody hemolytic anemia can often be differentiated from cold agglutinin disease by the temperature at which the direct antiglobulin test is positive; a test that is positive at temperatures ≥ 37° C indicates warm antibody hemolytic anemia, whereas a test that is positive at lower temperatures indicates cold agglutinin disease.
If PCH is suspected, the Donath-Landsteiner test, which is specific for PCH, should be done. In this test, the patient's serum is incubated with normal RBCs at 4° for 30 min to allow for fixation of complement and then warmed to body temperature. Hemolysis of the RBCs during this test is indicative of PCH. Because the PCH antibody fixes complement at low temperatures, the direct antiglobulin (direct Coombs) test is positive for C3 and negative for IgG. However, the antibody in PCH is an IgG against the P antigen.
Blood transfusion for severe, life-threatening anemia
For drug-induced warm antibody hemolytic anemia, drug withdrawal and sometimes IV immune globulin
For idiopathic warm antibody hemolytic anemia, corticosteroids and, in refractory cases, rituximab, IV immune globulin, or splenectomy
For cold agglutinin disease, avoidance of cold and treatment of underlying disorder
For PCH, avoidance of cold, immunosuppressants, and treatment of syphilis if present. In children, this disease is often self-resolving.
Blood transfusion is the most important treatment for symptomatic patients who rapidly develop severe, life-threatening anemia. In this situation, transfusion should never be withheld due to lack of "compatible" units. In general, patients who have not had a previous blood transfusion or been pregnant are at low risk for hemolysis of ABO-compatible blood. Even if transfused cells are hemolyzed, blood transfusion can be life-saving until more definitive therapy can be done.
Treatment depends on the specific mechanism of the hemolysis.
In drug-induced warm antibody hemolytic anemias, drug withdrawal decreases the rate of hemolysis. With alpha-methyldopa-type AIHA, hemolysis usually ceases within 3 wk; however, a positive antiglobulin test may persist for > 1 yr. With hapten-mediated AIHA, hemolysis ceases when the drug is cleared from the plasma. Corticosteroids have only little effect in drug-induced hemolysis; infusions of immune globulin may be more effective.
In idiopathic warm antibody AIHA, corticosteroids (eg, prednisone 1 mg/kg po once/day) are the standard first-line treatment. When stable RBC values are achieved, corticosteroids are tapered slowly with laboratory monitoring of hemolysis (eg, by Hb and reticulocyte count). The goal is to wean the patient completely from corticosteroids or to maintain remission with the lowest possible corticosteroid dose. About two-thirds of patients respond to corticosteroid treatment. In patients who relapse after corticosteroid cessation or who are refractory to corticosteroids, rituximab is usually used as a second-line drug.
Other treatments include use of additional immunosuppressive drugs and/or splenectomy. About one third to one half of patients have a sustained response after splenectomy.
In cases of fulminant hemolysis, high-dose pulse corticosteroids can be used. For less severe but uncontrolled hemolysis, immune globulin infusions have provided temporary control.
Long-term management with immunosuppressants (including cyclosporine) has been effective in patients in whom corticosteroids and splenectomy have been ineffective.
The presence of panagglutinating antibodies in warm antibody hemolytic anemia makes cross-matching of donor blood difficult. In addition, transfusions often superimpose an alloantibody on the autoantibody, accelerating hemolysis. Thus, transfusions should be avoided when anemia is not life-threatening.
In many cases, avoidance of cold environments and other triggers of hemolysis may be all that is needed to prevent symptomatic anemia.
In cases associated with a lymphoproliferative disease, treatment is directed at the underlying disorder. Rituximab is commonly used, and chemotherapy regimens used to treat B-cell cancers can be effective.
In severe cases, plasmapheresis is an effective temporary treatment. Transfusions should be given sparingly, with the blood warmed through an on-line warmer.
Splenectomy is usually of no value. and immunosuppressants have only modest effectiveness.
AIHA is divided into warm antibody hemolytic anemia and cold agglutinin disease based on the temperature at which the autoantibodies react with RBCs.
Hemolysis tends to be more severe in warm antibody hemolytic anemia and can be fatal.
Immunoglobulin and/or complement bound to the patient's RBCs is demonstrated by the occurrence of agglutination after antiglobulin serum is added to washed RBCs (positive direct antiglobulin test).
The pattern of the direct antiglobulin reaction can help distinguish warm antibody hemolytic anemia from cold agglutinin disease and sometimes identify the mechanism responsible for warm antibody hemolytic anemia.
Treatment is directed at the cause (including stopping drugs, avoiding cold, treating underlying disorder); IV immune globulin may be used for drug-induced AIHA, and immunosuppressants or splenectomy for idiopathic warm antibody hemolytic disease.